DNTH vs. RNA, MLTX, TGTX, ACAD, ARVN, INDV, SMMT, JANX, BHC, and RYTM
Should you be buying Dianthus Therapeutics stock or one of its competitors? The main competitors of Dianthus Therapeutics include Avidity Biosciences (RNA), MoonLake Immunotherapeutics (MLTX), TG Therapeutics (TGTX), ACADIA Pharmaceuticals (ACAD), Arvinas (ARVN), Indivior (INDV), Summit Therapeutics (SMMT), Janux Therapeutics (JANX), Bausch Health Companies (BHC), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical preparations" industry.
Dianthus Therapeutics (NASDAQ:DNTH) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, community ranking, media sentiment, earnings, risk and institutional ownership.
In the previous week, Avidity Biosciences had 3 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 7 mentions for Avidity Biosciences and 4 mentions for Dianthus Therapeutics. Avidity Biosciences' average media sentiment score of 1.03 beat Dianthus Therapeutics' score of 0.75 indicating that Avidity Biosciences is being referred to more favorably in the news media.
Dianthus Therapeutics has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.
Dianthus Therapeutics has higher earnings, but lower revenue than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Dianthus Therapeutics has a net margin of 0.00% compared to Avidity Biosciences' net margin of -2,103.78%. Dianthus Therapeutics' return on equity of -20.82% beat Avidity Biosciences' return on equity.
Dianthus Therapeutics presently has a consensus target price of $42.83, suggesting a potential upside of 101.76%. Avidity Biosciences has a consensus target price of $41.33, suggesting a potential upside of 55.33%. Given Dianthus Therapeutics' higher possible upside, equities analysts clearly believe Dianthus Therapeutics is more favorable than Avidity Biosciences.
Avidity Biosciences received 126 more outperform votes than Dianthus Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Dianthus Therapeutics an outperform vote while only 64.62% of users gave Avidity Biosciences an outperform vote.
47.5% of Dianthus Therapeutics shares are owned by institutional investors. 16.6% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 3.7% of Avidity Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Dianthus Therapeutics beats Avidity Biosciences on 10 of the 16 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding DNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dianthus Therapeutics Competitors List
Related Companies and Tools
